Orexo AB (publ) (LON:0H19)

Market Cap	103.70M
Revenue (ttm)	43.08M
Net Income (ttm)	-16.41M
Shares Out	n/a
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,200
Average Volume	156
Open	40.63
Previous Close	40.05
Day's Range	38.25 - 38.25
52-Week Range	9.24 - 41.20
Beta	0.66
RSI	67.43
Earnings Date	Oct 23, 2025

About Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ...

• Industry: Pharmaceutical Preparations
• Founded: 1994
• Employees: 110
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H19

Financial Performance

In 2024, Orexo AB's revenue was 590.00 million, a decrease of -7.64% compared to the previous year's 638.80 million. Losses were -203.00 million, 58.2% more than in 2023.

Financial numbers in SEK